Published on
March 22, 2019
- 11:27 GMT
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations …
Distribution channels:
Technology
...
